Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O4GU
|
||||
| Former ID |
DNC005747
|
||||
| Drug Name |
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
|
||||
| Indication | Discovery agent | Investigative | [527802] | ||
| Formula |
C50H66N10O10S2
|
||||
| Canonical SMILES |
CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC<br />CCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=C<br />C=C5)N)C(=O)NC(C=O)C(C)O
|
||||
| InChI |
1S/C50H66N10O10S2/c1-28(2)43-50(70)59-42(49(69)57-40(25-61)29(3)62)27-72-71-26-41(58-44(64)35(52)21-30-11-5-4-6-12-30)48(68)55-38(22-31-16-18-33(63)19-17-31)46(66)56-39(23-32-24-53-36-14-8-7-13-34(32)36)47(67)54-37(45(65)60-43)15-9-10-20-51/h4-8,11-14,16-19,24-25,28-29,35,37-43,53,62-63H,9-10,15,20-23,26-27,51-52H2,1-3H3,(H,54,67)(H,55,68)(H,56,66)(H,57,69)(H,58,64)(H,59,70)(H,60,65)/t29-,35+,37+,38+,39-,40-,41+,42-,43-/m1/s1
|
||||
| InChIKey |
KBXJEGQBFLLJFL-ILNSAXFWSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Somatostatin receptor type 5 | Target Info | Inhibitor | [527802] | |
| Somatostatin receptor type 2 | Target Info | Inhibitor | [527802] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| References | |||||